**Name of Journal: *World Journal of Hepatology***

**ESPS Manuscript NO: 21335**

**Manuscript Type: Minireviews**

**Hepatitis C and insulin action: An intimate relationship**

Knobler H *et al*. Insulin resistance and chronic HCV

**Hilla Knobler, Stephen Malnick**

**Hilla Knobler,** Diabetes and Metabolic Disease Unit, Kaplan Medical Center, Rehovot 76100, Israel

**Stephen Malnick,** Department of Internal Medicine C, Kaplan Medical Center, Rehovot 76100, Israel

**Author contributions:** Both authors contributed equally to this work.

**Conflict-of-interest statement:** None of the authors has any conflict of interest.

**Open-Access:** This article is an open-access article which was selected byan in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to:** **Hilla Knobler, MD,** Diabetes and Metabolic Disease Unit,Kaplan Medical Center, Pasternak St., Rehovot 76100, Israel. knobler@inter.net.il

**Telephone:** +972-8944-1650

**Fax:** +972-8944-1912

**Received:** July 6, 2015

**Peer-review started:** July 11, 2015

**First decision:** September 16, 2015

**Revised:** December 10, 2015

**Accepted:** December 29, 2015

**Article in press:**

**Published online:**

**Abstract**

Chronic hepatitis C virus (HCV) infection has been shown to be linked to a higher prevalence of type 2 diabetes compared with the general population or with patients with chronic hepatitis B infection and diabetes is the most common extra-hepatic manifestation of HCV. The HCV-diabetes association is due to insulin resistance (IR) that occurs early in the course of the disease even in patients without or with minimal fibrosis. The mechanisms for HCV-induced IR are only partly understood and include a direct inhibitory effect of HCV on insulin signaling pathway. IR in chronic HCV results in an increased progression rate of hepatic fibrosis, cirrhosis and hepatocellular carcinoma. Some but not all studies found that IR reduces the response rate to interferon/ ribavirin therapy. Whether IR affects the response to the new direct-acting antiviral treatments is still unknown.

**Key words:** Hepatitis C; Type 2 diabetes; Insulin resistance; Antiviral therapy; Insulin signaling

© **The Author(s) 2016**. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Chronic hepatitis C virus (HCV) infection is associated with a higher prevalence of diabetes as compared to either the general population or patients with chronic hepatitis B infections. HCV hepatitis is linked to insulin resistance (IR) early in the disease course, mediated partly by direct inhibitory effect of the viral proteins on insulin signaling. The presence of IR is associated with an increased rate of disease progression to fibrosis, cirrhosis and hepatocellular carcinoma. Interferon and ribavirin treatment of HCV hepatitis may be less successful in the presence of IR. The effect of IR on the new direct-acting antiviral treatment is unclear.

Knobler H, Malnick S. Hepatitis C and insulin action: An intimate relationship. *World J Hepatol* 2016; In press

**INTRODUCTION**

Chronic hepatitis C virus (HCV) infection is a major healthcare problem worldwide with between 130-170 million people infected[1,2]. In addition, there are extra-hepatic manifestations of HCV infection including mixed cryoglobulinemia, thyroid disorders and other autoimmune-mediated diseases[3], but several studies published since 1994 provide evidence that diabetes mellitus (DM) maybe the most common extra-hepatic disease associated with chronic HCV .

**The association between HCV and diabetes**

The first studies that demonstrated an association between HCV and DM evaluated patients at advanced stage of liver disease necessitating liver transplantation and revealed that diabetes occurred in 50% and 62% of patients whose liver failure was HCV-related compared to 9% in patients whose liver failure was related to other causes[4,5]. These unexpected results were confirmed by studies from many parts of the world demonstrating that the increased prevalence of diabetes in HCV patients is unique and is significantly different compared to hepatitis B virus (HBV) infection[6-8].

Many of these additional studies, however, also included patients with cirrhosis- a condition that by itself is known to lead to impaired glucose tolerance[9,10].

***Diabetes in non-cirrhotic HCV patients***

In order to avoid the confounding effect of cirrhosis on glucose metabolism, we designed a study conducted in patients without liver cirrhosis that included 45 patients with chronic HCV, 88 patients with chronic HBV infection and 90 healthy individuals[11]. Diabetes status was based on an oral glucose tolerance test (OGTT). We found that 33% of HCV patients had type 2 diabetes compared to 12% of patients with chronic HBV infection and 6% of a healthy control cohort. We have reported that HCV patients with diabetes had a higher incidence of a family history of diabetes as compared to HCV patients without diabetes (*P* < 0.001). In addition on comparing liver biopsies from HCV patients with diabetes to those with HCV and no diabetes there was a significantly higher inflammatory activity, fibrosis grade and more steatosis.

***Large cohort studies evaluating the relationship between HCV and diabetes***

The National Health and Nutrition Examination Survey (NHANES III) evaluated 9,841 community-dwelling subjects and found that 8% of this population had type 2 diabetes and 2% were anti-HCV positive. The odds ratio for type 2 DM in those over 40 years of age after adjusting for sex, body mass index (BMI), ethnicity, poverty index, and previous drug or alcohol use was 3.77 (95%CI: 1.80-7.87)[12]. There was no increased risk for DM in those with chronic HBV infection. Although liver biopsies were not performed in these patients, there were no clinical signs of chronic liver disease. A large study of consecutive chronic HCV patients from Spain, found a 3-fold increase in the prevalence of glucose abnormalities in non-cirrhotic HCV+ compared with HCV- subjects[13] but not in cirrhotic patients*.* Furthermore, multivariate analysis of chronic HCV patients without cirrhosis found that HCV infection was an independent determinant of glucose abnormalities, odds ratio of 4.26 (95%CI: 2.03-8.93). In the Atherosclerosis Risk in Communities (ARIC) Study, with a follow-up of 9-years pre-existing HCV infection was found to be a significant risk factor for developing diabetes in aged patients or those with a high BMI. This finding was strikingly robust with a relative hazard of 11.58 (95%CI: 1.39-96.6)[14]. Two meta-analyses including 47 cross-sectional and cohort studies found that HCV was associated with DM with an OR of 1.7[15,16] with an excess risk observed in comparison to HBV-infected controls.

However a recent additional report based on NHANES data 1999-2010 survey evaluated 15128 participants with known HCV and glucose status and did not find an association between HCV status and diabetes/pre-diabetes[17]. The reasons for this discrepancy are not entirely clear however the number of patients who were HCV positive was relatively small (1.7% were ant-HCV+ and 1.1% were HCV RNA+) and OGTT was not performed. Another factor that can reduce the strength of the association between HCV infection and diabetes in this recent United States survey is the increase within the last years of obesity rate and consequently obesity-induced diabetes that may dilute the effect of HCV.

Taken together, the vast majority of studies point that chronic hepatitis C is specifically associated with type 2 diabetes and the association is strongest in patients with additional risk factors such as older age and positive family history of diabetes implying that HCV leads to diabetes particularly in susceptible hosts.

***Interferon-induced diabetes***

Interferon treatment that was until recently the corner-stone of HCV treatment was shown to induce a distinct form of diabetes. However this is a relatively rare complication that in contrast to the common form of HCV-related type 2 diabetes described above, has an abrupt onset, necessitates insulin treatment from onset and is mediated by an autoimmune process manifested by a very high titer of pancreatic autoantibodies[18].

**Pathogenesis of hepatitis C associated diabetes**

***HCV and insulin resistance***

There is substantial evidence that insulin resistance (IR), that has a pivotal role in the pathogenesis of type 2 diabetes, develops early in the course of HCV infection[19–21]. A study of 260 subjects with HCV with assorted stages of fibrosis compared with 137 healthy volunteer in which IR was measured by the homeostasis model assessment (HOMA-IR), found significant IR even in the sub-group of 121 patients with only stage 0 or 1 of hepatic fibrosis,. However, although IR was detected even in subjects with minimal or no fibrosis, more advanced fibrosis was associated with increased HOMA-IR[19]. Other studies confirmed these findings and showed a correlation between the degree of fibrosis and IR[20,22]. By using the gold standard measurement of IR, the hyperinsulinemic- euglycemic clamp it was shown that IR occurred mainly in the periphery, *i.e.*, in muscles and not in the liver and was related to viral load but not to liver fat content[23]. The notion that HCV has a direct effect on insulin sensitivity that is not mediated by virus-induced steatosis is also supported by a transgenic mice model which expresses the HCV core protein in the liver. IR was detected as early as 1 mo of age while hepatic statosis developed after 3 mo[24]. In a landmark study, Aytug *et al*[25] evaluated liver specimens obtained from non-obese non-diabetic HCV patients compared to controls and their data not only confirmed the existence of HCV-induced IR but also revealed a specific impairment of insulin- stimulated IRS-1/PI3 kinase signaling pathway in HCV patients, a pathway that is responsible for insulin metabolic effects.

***IR and HCV genotypes***

The relationship between IR and HCV genotype is still controversial. In a study of Hui *et al*[19] patients with genotype 3 had significantly lower HOMA-IR compared with other genotypes and this association remained significant even after adjusting for other variables. In another large study of 275 non-diabetic treatment-naïve HCV patients, HOMA-IR was significantly higher in non-3 genotype compared with genotype 3. However in non-obese patients with minimal fibrosis, using a cut-off level of HOMA > 3 as indicating IR, there was no significant effect of genotypes[26]. In another smaller study of 44 patients that used a cut-off level of HOMA ≥ 2 as indicating IR, the prevalence of IR was similarly high, 65% and 57% in genotype 1 and genotype 3, respectively[27]. However it is important to emphasize that the usage of these HOMA-IR criteria to define IR is problematic since there are no acceptable absolute cut-off levels.

***The underlying mechanisms for HCV-induced IR***

**Tumor necrosis factor alpha:** The role of the cytokine tumor necrosis factor alpha (TNF-α) in HCV-induced IR is supported by several studies (for review[28]). TNF-α producing cells, the majority of which are derived from macrophage/Kupfer cell lineage, are increased in HCV infection; and TNF-α activation was found to be significantly associated with the inflammatory process[29]. TNF-α also has an important inhibitory role on the insulin signaling pathway and the mechanism is mediated by activating serine /threonine (Ser/Thr) kinases that phosphorylate the insulin receptor substrate (IRS) protein, and uncoupling it from both upstream and downstream effectors[30]. TNF-α induces IR also by indirect mechanisms such as increasing lipolysis leading to increased serum free fatty acids and regulating expression of several adipocyte genes that modulate insulin sensitivity[31]. TNF-α binds to two distinct cell surface receptors, TNFR-1 and TNFR-2 that undergo proteolytic cleavage producing soluble receptors sTNFR1 and sTNFR2. Serum levels of TNF-α and sTNFR were increased in HCV-infected patients compared with controls[32]. When serum sTNFR were measured in non-cirrhotic HCV patients with and without diabetes, non-HCV patients with type 2 diabetes and controls, a marked increase of sTNFR was found in the HCV-diabetes+ group compared to HCV patients without diabetes, and non-HCV patients with type 2 DM[33]. A significant correlation was found between the degree of liver inflammation and sTNFR[29]. The role of TNF-α in HCV-induced IR is supported by the finding that anti TNF-α antibody administration restored insulin sensitivity in a transgenic mice model that specifically expressed the HCV core protein in the liver[24].

However, increased levels of TNF-α are also present in other chronic liver diseases and thus cannot fully account for the unique association between HCV and IR. Therefore direct effects of HCV proteins on insulin signaling have been also considered.

***Direct effects of HCV proteins on insulin signaling***

 In human hepatoma cells, HCV core protein up-regulates suppressor cytokine signaling (SOCS)-3, which is known to inhibit insulin signaling by causing ubiquitination of IRS1 and IRS2 proteins[34]. These defects were not detected in SOCS3-/- mouse embryonic fibroblasts cells or in the presence of an inhibitor of proteosomal proteolysis[34]. We have reported several impairments of the insulin signaling cascade linked to the proteasomal degradation of IRS-1 protein[35]. Additionally we found that the core protein impaired insulin ability to inhibit the expression of the target gene insulin growth factor binding protein (IGFBP)-1.

HCV can also inhibit insulin signaling by dephosphorylation of AKT involving the endoplasmic reticulum (ER) stress signal inducing over-expression of protein phosphatase 2A[36]. Taken together these data imply a direct effect of HCV core protein in inhibiting insulin signaling pathway.

**Does eradication of HCV ameliorate IR?**

A recent study of 8 normoglycemic men with chronic HCV infection that used the hyperinsulinemic-euglycemic clamp that provides a direct measurement of peripheral insulin sensitivity, showed that viral clearance led to improvement in glycemic control and to insulin sensitivity that become comparable to 15 matched HCV-negative controls[37]. A larger earlier study, using the surrogate marker HOMA-IR also showed that in HCV patients who were sustained responders HOMA-IR decreased while in it did not change in nonresponders and relapsers[38]. However, another study showed that HCV therapy improved IR regardless of virologic response but the repose was greatly influenced by BMI changes and interferon use making data interpretation difficult[39].

**The effect of IR and DIABETES on the clinical outcome of HCV**

The link between HCV infection and IR and diabetes is complex. IR appears at an early stage of chronic HCV infection as discussed above and results in an increased rate of progression of hepatic fibrosis and the complications of cirrhosis including hepatocellular carcinoma (HCC)[40].

IR is also related to obesity and type 2 diabetes and both of these conditions are known to be risk factors for HCC leading to about 2-fold increased prevalence[41,42]. The rise in HCV infection and HCV-induced IR together with increased obesity-induced IR may partly explain the marked increase in HCC in the last decades[43].

The compensatory hyperinsulinemia that occurs in IR can lead to fibrogenesis. In human hepatic stellate cells (HSC), incubation with insulin and insulin growth factor (IGF)-1 led to increased HSC proliferation and type 1 collagen gene expression[44]. The increased IGF-1 levels that occur in the IR state is also one of the mechanisms for IR-associated malignancy and particularly HCC and changes in the expression pattern of IGF system components were found in human hepatoma cell lines and in animal models[45].

In a recent systemic review of 14 studies including 3695 participants with HCV infection, the relative risk for fibrosis was 2.26 (95%CI: 1.52-3.06) for genotype 1, but the association was not significant for genotype 3[46]. HCV is also intimately related to hepatic steatosis[47,48] and steatosis is much more common in patients infected with HCV than in other liver diseases. This association is most marked for genotype 3[49]. Steatosis is also linked to HCC and in two lines of transgenic mice expressing the HCV core protein, HCC developed within fat-containing adenomas[50].

**The effect of IR and diabetes on the response to therapy**

It has been shown that patients with high IR have a slower rate of decline in the viral load of HCV RNA compared to patients with low IR, even in the first 24 h of treatment[51]. In addition, there is an association between a high degree of IR and a low rate of rapid viral response (RVR) in genotypes 1[52], 3[53] and 4[54]. Several studies have shown that IR is associated with a higher likelihood of not achieving SVR[52–56]. A study from Spain of 159 patients with chronic HCV hepatitis found that those with a SVR had lower baseline HOMA scores compared to those patients who did not achieve a SVR[57]. The Virahep-C study which included both Caucasian and African-Americans found that IR and interferon dose were negatively associated with SVR[56]. The patients in this study had a high degree of obesity and IR as compared to other published reports. These studies have used HOMA to assess insulin sensitivity, a surrogate measure of IR although this technique is less precise than more direct measurements such as the insulin suppression test[58]. Furthermore IR can change over time with in patients with chronic HCV infection[59]. When IR was directly assessed by means of an insulin suppression test in a cohort of 50 non-cirrhotic, non-diabetic patients with chronic HCV infection, SVR was not associated with insulin sensitivity[39] The steady state plasma glucose level decreased during anti-viral therapy but was not statistically significant between those patients achieving SVR and those not achieving SVR during and after treatment[39]. IR often progresses to diabetes but in a study that evaluated SVR and the development of diabetes or impaired glucose tolerance, no such correlation was found during a median follow up of 8 years [60]. In 2011, two meta- analyses were published that examined the effect of IR on SVR including fourteen studies with more than 2700 patients[61,62]. The studies that did not find an association between IR and SVR had a baseline HOMA value of less than 3 and a low prevalence of advanced fibrosis. This suggests that the HOMA value may be predictive of response to antiviral treatment in those patients with advanced liver disease. These inconsistent data may be partly due the interplay between the baseline characteristics of the patients and the effect of the HCV virus on insulin sensitivity. Notably, about 25%-30% of the United States population have metabolic features of HCV-independent IR[63].

**Targeting IR as part of HCV treatment**

In view of the link between IR and the progression of HCV hepatitis and the possible influence of IR on treatment, attention has been drawn to improving the metabolic factors related to IR before or during anti-viral treatment.

***Lifestyle modification***

A 24 wk lifestyle and dietary intervention was shown to reduce BMI and HOMA in obese patients with chronic HCV hepatitis[64]. A 3-mo trial of a low calorie diet before starting anti-viral therapy has been shown to result in a higher end-of- treatment viral response in patients with type 1 chronic HCV hepatitis together with an improvement in IR.

***Metformin***

Metformin is an insulin sensitizer that mainly decreases hepatic glucose production. An attempt to add metformin to treatment with peg-interferon-2a and ribavirin led to decreased HOMA-IR and viral load, together with an improvement in the SVR, but this effect was observed only in females[65]. In another study metformin administration led to an increase in SVR in both male and female HCV patients with genotype 1 treated by pegylated interferon and ribavirin[66].

***Thiazolidinediones***

Thiazolidinediones produce an increase in insulin sensitivity *via* activation of the peroxisome proliferator-activated receptor - γ (PPAR-γ) in adipocytes and skeletal muscle[67]. Pioglitazone has been shown to produce an increase in SVR in patients with genotype 4 and IR but not in patients with genotype 1[68]. Another study of pioglitazone added to pegylated interferon-2a and ribavirin in non-diabetic HCV patients who previously did not respond to this treatment and who had HOMA > 2, was terminated after none of the first five patients achieved a 12 wk viral response, despite an improvement in IR in some of them[69].

In a recent small study of patients with HCC, in a sub-group analysis of diabetic over-weight patients, the addition of pioglitazone to curative treatment resulted in reduced HCC recurrence[70].

**The effect of diabetes on the response to the direct-acting anti-viral treatments**

The recently approved sofosbuvir, simeprevir, ledipasvir,and the combination of paritaprevir, ombitasvir and dasabuvir have ushered in the era of interferon-free therapy for HCV hepatitis. These direct-acting anti-viral treatments (DAA) achieve SVRs of more than 90% for most treatment groups[71]. With such an effective treatment available it is likely that the effect of IR will be less evident. However, a recent preliminary report suggests that metabolic factors such as diabetes and hyperlipidimia still compromise the effect of DAA treatment. This was based on the results of a recent study that examined SVR at 12-wk in 54 non-Caucasian populations in the United States, 65% of whom were Hispanic and 24% had diabetes. SVR in this study was 81% which is lower than the rate reported in previous studies. A pre-treatment glucose level of less than 126 mg/dL was shown to be linked to a higher rate of SVR[72]. Further studies are needed to evaluate the effect of IR and diabetes on the response to DAA treatment.

Although the future of treatment of HCV hepatitis will undoubtedly be oral, once-daily pangenotypic therapy with a nearly 100% SVR, in 2015 there is still a place for treatment of HCV hepatitis with interferon-containing regimens.

For patients with genotypes 2-6 peginterferon and ribavirin is still effective treatment. For patients with genotype 2, 24 wk of treatment is sufficient and an SVR of 85%-90% is achieved[73]. Interferon has an important role in the treatment of genotype 3 including a regimen with sofosbuvir[74]. For patients with genotype 4 SVR ranges from 43%-70% and 60%-85% for genotype 6[75].

In addition for many economically-constrained health services and patients who are self-funding. The cost of the DAAs is prohibitive, and treatment with interferon will remain an option for the near future[76].

**CONCLUSION**

IR is intimately related to HCV infection based on numerous studies in animal models and humans resulting in increased prevalence of type 2 diabetes in HCV patients. The underlying mechanisms are only partly understood and recent data suggest a direct inhibitory effect of the virus on insulin signaling pathway. IR was shown by several, but not all studies, to have a deleterious effect on the clinical course of chronic HCV infection and the inconsistency maybe explained by differences in the baseline characteristics of the patients. Small studies suggest that life-style intervention and metformin may increase SVR rate but further studies are needed to confirm these findings. The effect of IR in the DAA drugs era is still unclear.

**REFERENCES**

1 **Choo QL**, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science* 1989; **244**: 359-362 [PMID: 2523562]

2 **Ansaldi F**, Orsi A, Sticchi L, Bruzzone B, Icardi G. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. *World J Gastroenterol* 2014; **20**: 9633-9652 [PMID: 25110404 DOI: 10.3748/wjg.v20.i29.9633]

3 **Cacoub P**, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V, Yamamoto AM, Camproux AC, Hausfater P, Musset L, Veyssier P, Raguin G, Piette JC. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. *Medicine (Baltimore)* 2000; **79**: 47-56 [PMID: 10670409]

4 **Allison ME**, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. *J Hepatol* 1994; **21**: 1135-1139 [PMID: 7699240]

5 **Knobler H**, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH. Higher incidence of diabetes in liver transplant recipients with hepatitis C. *J Clin Gastroenterol* 1998; **26**: 30-33 [PMID: 9492860 DOI: 10.1097/00004836-199801000-00009]

6 **Fraser GM**, Harman I, Meller N, Niv Y, Porath A. Diabetes mellitus is associated with chronic hepatitis C but not chronic hepatitis B infection. *Isr J Med Sci* 1996; **32**: 526-530 [PMID: 8756978]

7 **Ozyilkan E**, Arslan M. Increased prevalence of diabetes mellitus in patients with chronic hepatitis C virus infection. *Am J Gastroenterol* 1996; **91**: 1480-1481 [PMID: 8678039]

8 **Grimbert S**, Valensi P, Lévy-Marchal C, Perret G, Richardet JP, Raffoux C, Trinchet JC, Beaugrand M. High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case-control study. *Gastroenterol Clin Biol* 1996; **20**: 544-548 [PMID: 8881566]

9 **Kruszynska YT**, Home PD, McIntyre N. Relationship between insulin sensitivity, insulin secretion and glucose tolerance in cirrhosis. *Hepatology* 1991; **14**: 103-111 [PMID: 2066059]

10 **Nolte W**, Hartmann H, Ramadori G. Glucose metabolism and liver cirrhosis. *Exp Clin Endocrinol Diabetes* 1995; **103**: 63-74 [PMID: 7553077 DOI: 10.1055/s-0029-1211331]

11 **Knobler H**, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. *Mayo Clin Proc* 2000; **75**: 355-359 [PMID: 10761489 DOI: 10.4065/75.4.355]

12 **Mehta SH**, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. *Ann Intern Med* 2000; **133**: 592-599 [PMID: 11033586 DOI: 10.7326/0003-4819-133-8-200010170-00009]

13 **Lecube A**, Hernández C, Genescà J, Esteban JI, Jardí R, Simó R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury. *Diabetes Care* 2004; **27**: 1171-1175 [PMID: 15111540 DOI: 10.2337/diacare.27.5.1171]

14 **Mehta SH**, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J, Szklo M, Thomas DL. Hepatitis C virus infection and incident type 2 diabetes. *Hepatology* 2003; **38**: 50-56 [PMID: 12829986 DOI: 10.1053/jhep.2003.50291]

15 **Naing C**, Mak JW, Ahmed SI, Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. *World J Gastroenterol* 2012; **18**: 1642-1651 [PMID: 22529694 DOI: 10.3748/wjg.v18.i14.1642]

16 **White DL**, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. *J Hepatol* 2008; **49**: 831-844 [PMID: 18814931 DOI: 10.1016/j.jhep.2008.08.006]

17 **Ruhl CE**, Menke A, Cowie CC, Everhart JE. Relationship of hepatitis C virus infection with diabetes in the U.S. population. *Hepatology* 2014; **60**: 1139-1149 [PMID: 24500979 DOI: 10.1002/hep.27047]

18 **Zornitzki T**, Malnick S, Lysyy L, Knobler H. Interferon therapy in hepatitis C leading to chronic type 1 diabetes. *World J Gastroenterol* 2015; **21**: 233-239 [PMID: 25574096 DOI: 10.3748/wjg.v21.i1.233]

19 **Hui JM**, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW, George J. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. *Gastroenterology* 2003; **125**: 1695-1704 [PMID: 14724822 DOI: 10.1053/j.gastro.2003.08.032]

20 **Petit JM**, Bour JB, Galland-Jos C, Minello A, Verges B, Guiguet M, Brun JM, Hillon P. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. *J Hepatol* 2001; **35**: 279-283 [PMID: 11580152 DOI: 10.1016/S0168-8278(01)00143-X]

21 **Sougleri M**, Labropoulou-Karatza C, Paraskevopoulou P, Fragopanagou H, Alexandrides T. Chronic hepatitis C virus infection without cirrhosis induces insulin resistance in patients with alpha-thalassaemia major. *Eur J Gastroenterol Hepatol* 2001; **13**: 1195-1199 [PMID: 11711776 DOI: 10.1097/00042737-200110000-00012]

22 **Hickman IJ**, Powell EE, Prins JB, Clouston AD, Ash S, Purdie DM, Jonsson JR. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. *J Hepatol* 2003; **39**: 1042-1048 [PMID: 14642624 DOI: 10.1016/S0168-8278(03)00463-X]

23 **Milner KL**, van der Poorten D, Trenell M, Jenkins AB, Xu A, Smythe G, Dore GJ, Zekry A, Weltman M, Fragomeli V, George J, Chisholm DJ. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. *Gastroenterology* 2010; **138**: 932-41.e1-3 [PMID: 19962985 DOI: 10.1053/j.gastro.2009.11.050]

24 **Shintani Y**, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, Moriya K, Koike K. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. *Gastroenterology* 2004; **126**: 840-848 [PMID: 14988838 DOI: 10.1053/j.gastro.2003.11.056]

25 **Aytug S**, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. *Hepatology* 2003; **38**: 1384-1392 [PMID: 14647049 DOI: 10.1016/j.hep.2003.09.012]

26 **Tsochatzis E**, Manolakopoulos S, Papatheodoridis GV, Hadziyannis E, Triantos C, Zisimopoulos K, Goulis I, Tzourmakliotis D, Akriviadis E, Manesis EK, Archimandritis AJ. Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study. *Aliment Pharmacol Ther* 2009; **30**: 947-954 [PMID: 19604179 DOI: 10.1111/j.1365-2036.2009.04094.x]

27 **Péres DP**, Cheinquer H, Wolf FH, Cheinquer N, Falavigna M, Péres LD. Prevalence of insulin resistance in chronic hepatitis C genotype 1 and 3 patients. *Ann Hepatol* 2013; **12**: 871-875 [PMID: 24114816]

28 **Knobler H**, Schattner A. TNF-{alpha}, chronic hepatitis C and diabetes: a novel triad. *QJM* 2005; **98**: 1-6 [PMID: 15625348 DOI: 10.1093/qjmed/hci001]

29 **Zylberberg H**, Rimaniol AC, Pol S, Masson A, De Groote D, Berthelot P, Bach JF, Bréchot C, Zavala F. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. *J Hepatol* 1999; **30**: 185-191 [PMID: 10068094 DOI: 10.1016/S0168-8278(99)80060-9]

30 **Zick Y**. Uncoupling insulin signalling by serine/threonine phosphorylation: a molecular basis for insulin resistance. *Biochem Soc Trans* 2004; **32**: 812-816 [PMID: 15494022 DOI: 10.1042/BST0320812]

31 **Ruan H**, Hacohen N, Golub TR, Van Parijs L, Lodish HF. Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. *Diabetes* 2002; **51**: 1319-1336 [PMID: 11978627 DOI: 10.2337/diabetes.51.5.1319]

32 **Itoh Y**, Okanoue T, Ohnishi N, Sakamoto M, Nishioji K, Nakagawa Y, Minami M, Murakami Y, Kashima K. Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection. *Am J Gastroenterol* 1999; **94**: 1332-1340 [PMID: 10235215 DOI: 10.1111/j.1572-0241.1999.01083.x]

33 **Knobler H**, Zhornicky T, Sandler A, Haran N, Ashur Y, Schattner A. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. *Am J Gastroenterol* 2003; **98**: 2751-2756 [PMID: 14687828 DOI: 10.1111/j.1572-0241.2003.08728.x]

34 **Kawaguchi T**, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, Taniguchi E, Kumemura H, Hanada S, Maeyama M, Baba S, Koga H, Kumashiro R, Ueno T, Ogata H, Yoshimura A, Sata M. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. *Am J Pathol* 2004; **165**: 1499-1508 [PMID: 15509521 DOI: 10.1016/S0002-9440(10)63408-6]

35 **Alberstein M**, Zornitzki T, Zick Y, Knobler H. Hepatitis C core protein impairs insulin downstream signalling and regulatory role of IGFBP-1 expression. *J Viral Hepat* 2012; **19**: 65-71 [PMID: 22187946 DOI: 10.1111/j.1365-2893.2011.01447.x]

36 **Bernsmeier C**, Duong FH, Christen V, Pugnale P, Negro F, Terracciano L, Heim MH. Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. *J Hepatol* 2008; **49**: 429-440 [PMID: 18486982 DOI: 10.1016/j.jhep.2008.04.007]

37 **Milner KL**, Jenkins AB, Trenell M, Tid-Ang J, Samocha-Bonet D, Weltman M, Xu A, George J, Chisholm DJ. Eradicating hepatitis C virus ameliorates insulin resistance without change in adipose depots. *J Viral Hepat* 2014; **21**: 325-332 [PMID: 24716635 DOI: 10.1111/jvh.12143]

38 **Kawaguchi T**, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, Nagao Y, Yanagimoto C, Hanada S, Koga H, Sata M. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. *Am J Gastroenterol* 2007; **102**: 570-576 [PMID: 17222321 DOI: 10.1111/j.1572-0241.2006.01038.x]

39 **Brandman D**, Bacchetti P, Ayala CE, Maher JJ, Khalili M. Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin action. *Diabetes Care* 2012; **35**: 1090-1094 [PMID: 22399695 DOI: 10.2337/dc11-1837]

40 **Mangia A**, Ripoli M. Insulin resistance, steatosis and hepatitis C virus. *Hepatol Int* 2013; **7 Suppl 2**: 782-789 [PMID: 24587848 DOI: 10.1007/s12072-013-9460-1]

41 **Hassan MM**, Abdel-Wahab R, Kaseb A, Shalaby A, Phan AT, El-Serag HB, Hawk E, Morris J, Singh Raghav KP, Lee JS, Vauthey JN, Bortus G, Torres HA, Amos CI, Wolff RA, Li D. Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. *Gastroenterology* 2015; **149**: 119-129 [PMID: 25836985 DOI: 10.1053/j.gastro.2015.03.044]

42 **El-Serag HB**, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. *Gastroenterology* 2004; **126**: 460-468 [PMID: 14762783 DOI: 10.1053/j.gastro.2003.10.065]

43 **El-Serag HB**. Hepatocellular carcinoma: recent trends in the United States. *Gastroenterology* 2004; **127**: S27-S34 [PMID: 15508094 DOI: 10.1053/j.gastro.2004.09.013]

44 **Svegliati-Baroni G**, Ridolfi F, Di Sario A, Casini A, Marucci L, Gaggiotti G, Orlandoni P, Macarri G, Perego L, Benedetti A, Folli F. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. *Hepatology* 1999; **29**: 1743-1751 [PMID: 10347117 DOI: 10.1002/hep.510290632]

45 **Alexia C**, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. *Biochem Pharmacol* 2004; **68**: 1003-1015 [PMID: 15313394 DOI: 10.1016/j.bcp.2004.05.029]

46 **Patel S**, Jinjuvadia R, Patel R, Liangpunsakul S. Insulin Resistance is Associated With Significant Liver Fibrosis in Chronic Hepatitis C Patients: A Systemic Review and Meta-Analysis. *J Clin Gastroenterol* 2016; **50**: 80-84 [PMID: 26302498 DOI: 10.1097/MCG.0000000000000400]

47  **Dev A**, Patel K, McHutchison JG. Hepatitis C and steatosis. *Clin Liver Dis* 2004; **8**: 881-92, ix [PMID: 15464660 DOI: 10.1016/j.cld.2004.06.007]

48 **Abenavoli L**, Masarone M, Peta V, Milic N, Kobyliak N, Rouabhia S, Persico M. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. *World J Gastroenterol* 2014; **20**: 15233-15240 [PMID: 25386071 DOI: 10.3748/wjg.v20.i41.15233]

49 **Lonardo A**, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. *Gastroenterology* 2004; **126**: 586-597 [PMID: 14762795 DOI: 10.1053/j.gastro.2003.11.020]

50 **Moriya K**, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. *Nat Med* 1998; **4**: 1065-1067 [PMID: 9734402 DOI: 10.1038/2053]

51 **Bortoletto G**, Scribano L, Realdon S, Marcolongo M, Mirandola S, Franceschini L, Bonisegna S, Noventa F, Plebani M, Martines D, Alberti A. Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance. *J Viral Hepat* 2010; **17**: 475-480 [PMID: 19878535 DOI: 10.1111/j.1365-2893.2009.01204.x]

52 **Grasso A**, Malfatti F, De Leo P, Martines H, Fabris P, Toscanini F, Anselmo M, Menardo G. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. *J Hepatol* 2009; **51**: 984-990 [PMID: 19695729 DOI: 10.1016/j.jhep.2009.07.008]

53 **Fattovich G**, Covolo L, Pasino M, Perini E, Rossi L, Brocco G, Guido M, Cristofori C, Belotti C, Puoti M, Gaeta GB, Santantonio T, Raimondo G, Bruno R, Minola E, Negro F, Donato F. The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. *Liver Int* 2011; **31**: 66-74 [PMID: 20840397 DOI: 10.1111/j.1478-3231.2010.02343.x]

54 **Khattab M**, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. *Am J Gastroenterol* 2010; **105**: 1970-1977 [PMID: 20234345 DOI: 10.1038/ajg.2010.110]

55 **Moucari R**, Ripault MP, Martinot-Peignoux M, Voitot H, Cardoso AC, Stern C, Boyer N, Maylin S, Nicolas-Chanoine MH, Vidaud M, Valla D, Bedossa P, Marcellin P. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. *Gut* 2009; **58**: 1662-1669 [PMID: 19671541 DOI: 10.1136/gut.2009.185074]

56 **Conjeevaram HS**, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, Wahed AS. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. *Hepatology* 2007; **45**: 80-87 [PMID: 17187406 DOI: 10.1002/hep.21455]

57 **Romero-Gómez M**, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Corpas R, Cruz M, Grande L, Vázquez L, Muñoz-De-Rueda P, López-Serrano P, Gila A, Gutiérrez ML, Pérez C, Ruiz-Extremera A, Suárez E, Castillo J. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. *Gastroenterology* 2005; **128**: 636-641 [PMID: 15765399 DOI: 10.1053/j.gastro.2004.12.049]

58 **Lam KD**, Bacchetti P, Abbasi F, Ayala CE, Loeb SM, Shah V, Wen MJ, Reaven GM, Maher JJ, Khalili M. Comparison of surrogate and direct measurement of insulin resistance in chronic hepatitis C virus infection: impact of obesity and ethnicity. *Hepatology* 2010; **52**: 38-46 [PMID: 20578127 DOI: 10.1002/hep.23670]

59 **Park SK**, Cho YK, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK, Kim BI. Change of insulin sensitivity in hepatitis C patients with normal insulin sensitivity: a 5-year prospective follow-up study variation of insulin sensitivity in HCV patients. *Intern Med J* 2010; **40**: 503-511 [PMID: 19712201 DOI: 10.1111/j.1445-5994.2009.02042.x]

60 **Giordanino C**, Bugianesi E, Smedile A, Ciancio A, Abate ML, Olivero A, Pellicano R, Cassader M, Gambino R, Bo S, Ciccone G, Rizzetto M, Saracco G. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. *Am J Gastroenterol* 2008; **103**: 2481-2487 [PMID: 18702647 DOI: 10.1111/j.1572-0241.2008.02002.x]

61 **Eslam M**, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. *Aliment Pharmacol Ther* 2011; **34**: 297-305 [PMID: 21623851 DOI: 10.1111/j.1365-2036.2011.04716.x]

62 **Deltenre P**, Louvet A, Lemoine M, Mourad A, Fartoux L, Moreno C, Henrion J, Mathurin P, Serfaty L. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. *J Hepatol* 2011; **55**: 1187-1194 [PMID: 21703195 DOI: 10.1016/j.jhep.2011.03.010]

63 **Falkner B**, Cossrow ND. Prevalence of metabolic syndrome and obesity-associated hypertension in the racial ethnic minorities of the United States. *Curr Hypertens Rep* 2014; **16**: 449 [PMID: 24819559 DOI: 10.1007/s11906-014-0449-5]

64 **Pattullo V**, Duarte-Rojo A, Soliman W, Vargas-Vorackova F, Sockalingam S, Fantus IG, Allard J, Heathcote J. A 24-week dietary and physical activity lifestyle intervention reduces hepatic insulin resistance in the obese with chronic hepatitis C. *Liver Int* 2013; **33**: 410-419 [PMID: 23278982 DOI: 10.1111/liv.12041]

65 **Romero-Gómez M**, Diago M, Andrade RJ, Calleja JL, Salmerón J, Fernández-Rodríguez CM, Solà R, García-Samaniego J, Herrerías JM, De la Mata M, Moreno-Otero R, Nuñez O, Olveira A, Durán S, Planas R. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. *Hepatology* 2009; **50**: 1702-1708 [PMID: 19845037 DOI: 10.1002/hep.23206]

66 **Yu JW**, Sun LJ, Zhao YH, Kang P, Yan BZ. The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance. *Int J Infect Dis* 2012; **16**: e436-e441 [PMID: 22486858 DOI: 10.1016/j.ijid.2012.02.004]

67 **Harrison SA**. Liver disease in patients with diabetes mellitus. *J Clin Gastroenterol* 2006; **40**: 68-76 [PMID: 16340637 DOI: 10.1097/01.mcg.0000190774.91875.d2]

68 **Harrison SA**, Hamzeh FM, Han J, Pandya PK, Sheikh MY, Vierling JM. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. *Hepatology* 2012; **56**: 464-473 [PMID: 22334369 DOI: 10.1002/hep.25661]

69 **Overbeck K**, Genné D, Golay A, Negro F. Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. *J Hepatol* 2008; **49**: 295-298 [PMID: 18555553 DOI: 10.1016/j.jhep.2008.03.033]

70 [**Sumie S**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Sumie%20S%5BAuthor%5D&cauthor=true&cauthor_uid=25469280)**,**[Kawaguchi T](http://www.ncbi.nlm.nih.gov/pubmed/?term=Kawaguchi%20T%5BAuthor%5D&cauthor=true&cauthor_uid=25469280), [Kawaguchi A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Kawaguchi%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25469280), [Kuromatsu R](http://www.ncbi.nlm.nih.gov/pubmed/?term=Kuromatsu%20R%5BAuthor%5D&cauthor=true&cauthor_uid=25469280), [Nakano M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Nakano%20M%5BAuthor%5D&cauthor=true&cauthor_uid=25469280), [Satani M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Satani%20M%5BAuthor%5D&cauthor=true&cauthor_uid=25469280), [Yamada S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Yamada%20S%5BAuthor%5D&cauthor=true&cauthor_uid=25469280), [Okamura S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Okamura%20S%5BAuthor%5D&cauthor=true&cauthor_uid=25469280), [Yonezawa Y](http://www.ncbi.nlm.nih.gov/pubmed/?term=Yonezawa%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=25469280), [Kakuma T](http://www.ncbi.nlm.nih.gov/pubmed/?term=Kakuma%20T%5BAuthor%5D&cauthor=true&cauthor_uid=25469280), [Torimura T](http://www.ncbi.nlm.nih.gov/pubmed/?term=Torimura%20T%5BAuthor%5D&cauthor=true&cauthor_uid=25469280), [Sata M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Sata%20M%5BAuthor%5D&cauthor=true&cauthor_uid=25469280). Effect of pioglitazone on outcome following curative treatment for hepatocellular carcinoma in patients with hepatitis C virus infection: A prospective study. *Mol Clin Oncol* 2015; **3**: 115-120 [PMID: 25469280 DOI: 10.3892/mco.2014.435]

71 **Pawlotsky JM**, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. *J Hepatol* 2015; **62**: S87-S99 [PMID: 25920094 DOI: 10.1016/j.jhep.2015.02.006]

72 **Nasrollah L,** Backstedt DW, Pedersen MR, Choi M, Seetharam AB. Tu1022 Diabetes and hyperlipidemia compromise practical effectiveness of direct acting antiviral HCV therapy in minority populations. *Gastroenterology* 2015; **148 (Suppl 1):** S-1087 [DOI: 10.1016/S0016-5085(15)33711-2]

73 **Webster DP**, Klenerman P, Dusheiko GM. Hepatitis C. *Lancet* 2015; **385**: 1124-1135 [PMID: 25687730 DOI: 10.1016/S0140-6736(14)62401-6]

74 **Gondeau C**, Pageaux GP, Larrey D. Hepatitis C virus infection: Are there still specific problems with genotype 3? *World J Gastroenterol* 2015; **21**: 12101-12113 [PMID: 26576095 DOI: 10.3748/wjg.v21.i42.12101]

75 **Antaki N**, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, Gadano A, Zein N, Lai CL, Pawlotsky JM, Heathcote EJ, Dusheiko G, Marcellin P. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. *Liver Int* 2010; **30**: 342-355 [PMID: 20015149 DOI: 10.1111/j.1478-3231.2009.02188.x]

76 **Lim SG**. Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settings. *World J Gastroenterol* 2015; **21**: 1972-1981 [PMID: 25684966 DOI: 10.3748/wjg.v21.i6.1972]

**P- Reviewer:** Kovacs SJ, Liang J **S- Editor:** Song XX **L- Editor:** **E- Editor:**